Paper Details

  1. Home
  2. Paper Details

Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review.

Author: GaoShan, HaoYanrong, WeiGuanjing

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

This case report describes a patient with HR+HER2- advanced metastatic breast cancer who developed vitiligo-like lesions after 10 months of taking Palbociclib, a CDK4/6 inhibitor. This unusual adverse event highlights the need for clinician awareness and further research on skin toxicity associated with CDK4/6 inhibitors.
Paper Details　
Original Abstract of the Article :
Endocrine therapy has played an essential role in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. With the continuous development of endocrine targeting drugs, especially the emergence of selective cyclin-dependent kinase (CDK4/6) inhibitors,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358287/

データ提供：米国国立医学図書館（NLM）

Vitiligo-like Lesions Induced by Palbociclib: A Case Report and Literature Review

The field of cancer treatment is constantly evolving, with the development of new drugs and therapies. This research focuses on a rare side effect of Palbociclib, a cyclin-dependent kinase (CDK4/6) inhibitor used in the treatment of breast cancer. The authors report a case of vitiligo-like lesions that developed in a patient receiving Palbociclib and provide a comprehensive review of the existing literature on skin toxicities associated with CDK4/6 inhibitors.

Rare Skin Toxicity: Palbociclib and Vitiligo-like Lesions

The case report highlights a unique observation: the emergence of vitiligo-like lesions in a patient treated with Palbociclib. This finding is noteworthy as skin toxicity is a rare adverse event associated with CDK4/6 inhibitors. While the exact mechanism underlying this side effect is unclear, it adds to our understanding of the potential dermatological complications associated with these drugs.

Awareness and Vigilance: Implications for Clinicians

This study serves as a reminder for clinicians to be aware of the potential for uncommon side effects, even those not widely reported, when prescribing CDK4/6 inhibitors. Close monitoring and prompt identification of any skin changes are crucial for early intervention and management of potential adverse effects. The authors emphasize the need for further research to elucidate the mechanism behind these rare skin toxicities and to develop strategies for prevention or treatment.

Dr. Camel's Conclusion

My dear friends, this study reminds us that even in the vast desert of medical knowledge, there are still hidden oases to discover. Just as a rare desert flower can bloom in unexpected places, this case report highlights the importance of vigilance and a keen eye for the subtle details of patient health. It's a reminder that even in the most advanced therapies, there can be unexpected side effects, and we must be prepared to navigate these uncharted territories with care and compassion.
Date :
  1. Date Completed 2023-07-25
  2. Date Revised 2023-07-25
Further Info :

Pubmed ID

37483648

DOI: Digital Object Identifier

PMC10358287

Related Literature

Article Analysis
・Side Effects of palbociclib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.